Stock Price Quote

TATVA CHINTAN PHARMA CHEM LTD.

NSE : TATVABSE : 543321ISIN CODE : INE0GK401011Industry : ChemicalsHouse : Private
BSE1743.5057.05 (+3.38 %)
PREV CLOSE ( ) 1686.45
OPEN PRICE ( ) 1693.90
BID PRICE (QTY) 1733.90 (80)
OFFER PRICE (QTY) 1741.30 (31)
VOLUME 2721
TODAY'S LOW / HIGH ( )1691.00 1745.05
52 WK LOW / HIGH ( )988 1838.85
NSE1738.2049.8 (+2.95 %)
PREV CLOSE( ) 1688.40
OPEN PRICE ( ) 1692.00
BID PRICE (QTY) 1736.50 (5)
OFFER PRICE (QTY) 1738.20 (15)
VOLUME 24935
TODAY'S LOW / HIGH( ) 1689.10 1745.00
52 WK LOW / HIGH ( )981.5 1838.1
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 12-06 1996
Management Info
Chintan Nitinkumar Shah - Chairman Chintan Nitinkumar Shah - Managing Director
Registered Office

Address Plot No 502/17,G I D C Estate,Ankleshwar,
Bharuch Dist,
Gujarat-393002

Phone 07574848533 / 34

Email cs@tatvachintan.com

Website www.tatvachintan.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

18Aug Tatva Chintan Pharma Chem informs abou
Pursuant to Regulation 30 read with Schedule III Part A Para A and Regul..
18Jul Tatva Chintan Pharma Chem informs abou
Pursuant to regulation 30 and 47 of the Securities and Exchange Board of..
10Jul Tatva Chintan Pharma Chem informs abou
Tatva Chintan Pharma Chem has informed that the meeting of the Board of..
19May Tatva Chintan Pharma Chem informs abou
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
19Mar Tatva Chintan Pharma Chem informs abou
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit104.46390.82
Gross Profit 140.94 531.65
Operating Profit 280.58928.58
Net Sales 1467.024962.96

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Foseco India (BSE)
peergroup  6300.00 (3.75%)
M.Cap ( in Cr)4576.66
Gujarat Fluorochem. (BSE)
peergroup  4849.75 (2.02%)
M.Cap ( in Cr)52220.49
Atul (BSE)
peergroup  6281.25 (1.02%)
M.Cap ( in Cr)18305.85
Neogen Chemicals (BSE)
peergroup  2295.90 (2.23%)
M.Cap ( in Cr)6149.51
Balaji Amines (BSE)
peergroup  2395.20 (1.52%)
M.Cap ( in Cr)7644.37

Shareholding Pattern

PROMOTERS 72.02%
NON-INSTITUTION 20.94%
MUTUAL FUNDS/UTI 2.79%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Tatva Chintan Pharma Chem Ltd.

Tatva Chintan Pharma Chem Ltd. was incorporated in the year 1996. Its today's share price is 1743.5. Its current market capitalisation stands at Rs 3944.95 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4969.05 Cr and Total Income of Rs.4998.24 Cr. The company's management includes Subhash Ambubhai Patel, Manher Chimanlal Desai, Avani Rajesh Umatt, Shekhar Rasiklal Somani, Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, Chintan Nitinkumar Shah, Ishwar Nayi.

It is listed on the BSE with a BSE Code of 543321 , NSE with an NSE Symbol of TATVA and ISIN of INE0GK401011. It's Registered office is at Plot No 502/17,G I D C Estate,AnkleshwarBharuch Dist-393002, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are NDJ & Co, Pathak Anjaria & Co.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.